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An increase in fracture risk has been reported in patients with type 2 diabetes mellitus (T2DM) treated with canagliflozin, possibly mediated by effects induced by all members of the sodiumglucose co-transporter-2 (SGLT2) inhibitor class. It is unclear whether initiation of dapagliflozin is followed by an increase in the risk of fracture; therefore, we performed a population-based, open cohort study (from January 2013 to January 2016) using The Health Improvement Network (THIN). A total of 22 618 people with T2DM (4548 exposed to dapagliflozin and 18 070 receiving standard antidiabetic treatment, matched for age, sex, body mass index and diabetes duration) with no history of fractures at baseline were included. The primary outcome was the occurrence of any fragility fracture (hip, spine, wrist) during the observation period. Risk of any fracture served as a secondary outcome. Adjusted hazard rate ratios (HRs) with 95% confidence intervals (CIs) were calculated using Cox regression. A total of 289 fractures (132 fragility fractures) were recorded. No difference in the risk of fragility fracture was detected between participants prescribed dapagliflozin and matched control participants (crude HR 0.90, 95% CI 0.59-1.39, P = .645; adjusted HR 0.87, 95% CI 0.56-1.35, P = .531). Similarly, no difference in the risk of any fracture was detected (adjusted HR 0.89, 95% CI 0.66-1.20; P = .427). Sensitivity analyses limited to the subset of the population at high risk of fracture produced similar results; thus, there was no evidence to suggest an increase in the risk of treatment-emergent fractures in patients with T2DM who initiated treatment with dapagliflozin. therefore, any factor that might, even incrementally, affect this risk should be of concern in the management of T2DM.
The less-pronounced systemic effects of sodium-glucose cotransporter-2 (SGLT2) inhibitors (canaglifozin, dapagliflozin and empaglifozin)
are not yet fully elucidated. In particular, concerns are raised about their potential detrimental effect on the skeleton and eventually on the risk of fracture. In line with evidence suggesting a decrease in total hip body mass density 3 and increased risk of frac-of dapagliflozin on bone turnover markers, 7, 8 it is still unclear whether the fracture risk is higher in these patients.
The aim of the present study was to explore whether initiating treatment with dapagliflozin in patients with T2DM and no evidence of fractures at baseline was associated with an increased risk of fractures in the short term.
| MATERIALS AND METHODS

| Study design
We designed and performed a population-based, retrospective open cohort study in which people exposed to dapagliflozin (exposed cohort) were compared with matched people with T2DM unexposed to SGLT2 inhibitors (unexposed or control cohort). Age, sex, body mass index and duration of T2DM were the variables used for matching, which was performed using a computerized procedure. 9 Data were derived from The Health Improvement Network (THIN), a UK general practice electronic database, from January 1, 2013 (study start) to January 1, 2016 (study end, last collection date).
| Study cohort
Individuals were included in the exposed cohort if they were aged ≥40 years, had >3 months of treatment with a dapagliflozin and had remained at their practice at least 3 months after treatment initiation.
For each exposed paricipant, up to four unexposed control participants were selected by matching. Controls were also required to have a diagnosis of T2DM before or at their index date and were not exposed to any SGLT2 inhibitor throughout the study.
| Follow-up, outcomes and covariates
The primary outcome was incident fragility fracture (vertebral, femoral, humerus, distal radius) identified during the observation period.
Incidence of any fracture served as a secondary outcome. Estimated glomerular filtration rate, glycated haemoglobin (HbA1c), insulin therapy, anti-osteoporotic medications, metastatic bone disease, connective tissue disorder, hyperthyroidism, active smoking, social deprivation quintile and oral steroid treatment were used as covariates in the primary analysis.
| Sensitivity analyses
We performed pre-planned sensitivity analyses, firstly, by limiting them to people considered to be at a higher risk of fracture, and secondly, by adding use of thiazolidinediones (TZD) or sulphonylureas (SU) as covariates in the primary analysis. In the former, participants were considered to be at a higher risk of fracture if they were either aged ≥65 years or had a diagnosis associated with altered bone turnover (hyperthyroidism, connective tissue disorder, metastatic bone disease, steroid use and osteoporosis under treatment). The latter analysis was performed to control for the TZD-associated decrease in osteoblastogenesis 10 and the SU-associated increase in hypoglycaemic events (and possibly the resulting increased risk of falls). 11 3 | RESULTS
| Statistical analysis
| Cohort characteristics
The study population included 22 618 participants (4548 with T2DM exposed to dapagliflozin [exposed cohort] and 18 070 with T2DM, unexposed to an SGLT2 inhibitor [control cohort]). The study population was followed up for a mean (range) of~12.0 (36) months and a total of~23 000 person-years. Men constituted 43% of the study population and virtually all participants (99.7%) were aged >50 years.
The mean age and body mass index were 59.4 years and 34.5 kg/m 2 , respectively, the mean duration of diabetes was~10 years and the mean HbA1c in the total study population was 7.8% (62 mmol/mol).
A total of 289 fractures were recorded during the observation period, 132 of which were fractures of the proximal femoral, vertebrae, distal radius and humerus, collectively considered as fragility fractures. The event rate for any fracture was estimated at~12 per 1000 person-years in the exposed cohort. A table summarizing key study characteristics on the basis of exposure to dapagliflozin is presented in Table 1 .
| Risk of incident fragility fracture
No difference in the risk of fragility fracture was detected between people with diabetes who were administered dapagliflozin and matched controls (crude HR 0.90, 95% CI 0.59-1.39; P = .645 [- Table 2] ). This finding did not change after adjusting for key covariates (adjusted HR 0.87, 95% CI 0.56-1.35; P = .531 [ Table 2 ]).
| Risk of any fracture
Similarly, no difference in the risk of any fracture was detected between people with diabetes who were administered dapagliflozin and matched controls (crude HR 0.93, 95% CI 0.69-1.23, P = .601; adjusted HR 0.89, 95% CI 0.66-1.20, P = .427 [ Table 2 ]).
| Sensitivity analyses
No differences in the risk of fragility fracture or any fracture were Table S2 , Appendix S1]). Abbreviation: HbA1c, glycated haemoglobin. Continuous data presented as mean (SD) unless otherwise specified. Dichotomous and ordinal data presented as n (%). Townsend index is a measure of material deprivation (1 denotes the least deprived and 5 the most deprived individuals). 
